Blueprint Medicines Corporation (BPMC) News

Blueprint Medicines Corporation (BPMC): $61.17

-7.38 (-10.77%)

POWR Rating

Component Grades













Add BPMC to Watchlist
Sign Up

Industry: Biotech


of 402

in industry

Filter BPMC News Items

BPMC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BPMC News Highlights

  • BPMC's 30 day story count now stands at 10.
  • Over the past 15 days, the trend for BPMC's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about BPMC are BEAT and RARE.

Latest BPMC News From Around the Web

Below are the latest news stories about Blueprint Medicines Corp that investors may wish to consider to help them evaluate BPMC as an investment opportunity.

Blueprint Medicines (BPMC) Q4 Loss Widens, Revenues Top Mark

Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.

Yahoo | February 17, 2022

Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -39.44% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 16, 2022

Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results

Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2021.

Yahoo | February 16, 2022

Blueprint Medicines to Present at Upcoming Investor Conferences

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences.

Yahoo | February 11, 2022

Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 9, 2022

Blueprint Medicines to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 16, 2022

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, February 16, 2022 to report its fourth quarter and full year 2021 financial results and provide a corporate update.

Yahoo | February 9, 2022

Were Hedge Funds Right About Blueprint Medicines Corporation (BPMC)?

Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January.

Insider Monkey | February 7, 2022

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on February 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 26,212 shares of its common stock and an aggregate of 13,103 restricted stock units (RSUs) to fifteen new employees under Blueprint Medicines' 2020 Inducemen

Yahoo | February 4, 2022

AGF Investments LLC Buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The ...

Investment company AGF Investments LLC (Current Portfolio) buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The Energy Select Sector SPDR Fund, Paratek Pharmaceuticals Inc, Hello Group Inc, sells Industrial Select Sector SPDR, Consumer Staples Select Sector SPDR, Utilities Select Sector SPDR ETF, Microsoft Corp, UnitedHealth Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, AGF Investments LLC.

Yahoo | February 2, 2022

EMA''s Advisory Committee Recommends Approval Of Blueprint Medicines'' Avapritinib In Blood Disorder

The European Medicines Agency''s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the use of Blueprint Medicines Corporation''s (NASDAQ: BPMC ) Ayvakyt (avapritinib). The positive opinion covers Ayvakyt as monotherapy for aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological … Full story available on

Benzinga | January 28, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8244 seconds.